---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-056039"
form_type: "8-K"
ticker: "PLUR"
cik: "0001158780"
company_name: "Pluri Inc."
filed_at: "2023-07-11T23:59:59+00:00"
generated_at: "2026-06-13T09:47:51.736792+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Pluri signs $4.2M NIAID contract to develop PLX-R18 cell therapy for H-ARS

## Summary
- Three-year, $4.2M contract with NIAID to advance PLX-R18 for Hematopoietic Acute Radiation Syndrome (H-ARS).
- Company will collaborate with U.S. DOD's AFRRI and Uniformed Services University of Health Sciences (USUHS).
- Program funded by NIAID, part of the National Institutes of Health (NIH).
- PLX-R18 is a potential novel treatment for radiation exposure from nuclear disasters.

## SEC filing metadata
- accession: 0001213900-23-056039
- form_type: 8-K
- ticker: PLUR
- cik: 0001158780
- company_name: Pluri Inc.
- filed_at: 2023-07-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1158780/000121390023056039/0001213900-23-056039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1158780/000121390023056039/ea181617-8k_pluriinc.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-056039
- JSON: https://secwatch.observer/filing/0001213900-23-056039.json
- Plain text: https://secwatch.observer/filing/0001213900-23-056039.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.